Company
Every investor coverage indicates participated in a round Tulane University raised.
Companies Tulane University acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Paul K. Whelton | Show Chwan Chair in Global Public Health | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming Tulane University. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
George Medicines has begun two Phase III trials testing its triple-combination pill GMRx2 as a first-line hypertension treatment, with patient availability possible by 2023 pending US regulatory approval.
Drug developer George Medicines has started two Phase III trials of its GMRx2 triple-combination pill as a first-line hypertension therapy, enrolling patients across seven countries, with possible availability by 2023 pending US regulator approval.